Arimoclomol FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 31, 2023.
FDA Approved: No
Generic name: arimoclomol
Company: Zevra Therapeutics, Inc.
Treatment for: Niemann-Pick Disease
Arimoclomol is an investigational heat shock protein amplifier in development for the treatment of Niemann-Pick disease Type C (NPC).
Development timeline for arimoclomol
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.